SacropeniaNCT07915310
Multimodal Assessment of Sarcopenia Using Shear Wave Elastography, Dual-Energy X-ray Absorptiometry, Bioelectrical Impedance Analysis, and Physical Performance Measures
An observational study of Sacropenia, run by Kaohsiung Veterans General Hospital. at 1 site in Taiwan.
Trial summary
The goal of this observational study is to learn whether shear wave elastography (SWE) parameters, combined with dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and physical performance assessments, can help diagnose sarcopenia in older adults. Read more about this study
- Who is it for?
- Ages 65 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sacropenia
- How many people
- 100 participants
- Where
- 1 siteTaiwan
- Study dates
- 21 Oct 2026to Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Study population: Participants will be recruited from the outpatient clinics or inpatient ward of Kaohsiung Veterans General Hospita, Taiwan.
Who may be able to join
- Adults aged 65 years and older
- Able to walk independently, with or without an assistive device
- Able to understand study procedures and provide written informed consent
- Able to perform related exam
Who cannot join
- Implanted electronic medical devices (e.g., cardiac pacemaker or defibrillator), which contraindicate BIA measurement
- Metal implants or prostheses in the regions measured by DXA or ultrasound
- History of fracture or surgery of the lower extremities within the past 6 months
- Neuromuscular disease affecting skeletal muscle (e.g., stroke with residual limb weakness, Parkinson's disease, myopathy, or amyotrophic lateral sclerosis)
- Skin lesions, wounds, or infection at the ultrasound measurement sites
- Acute illness or hospitalization within the past 4 weeks
- Cognitive impairment or psychiatric conditions that preclude completion of study assessments
- Inability to complete muscle strength or physical performance tests
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
Kaohsiung Veterans General Hospital
Kaohsiung City, 807
Ming Hsuan Huang, 886-0933603324, tatat6918@gmail.com
About this study
The goal of this observational study is to learn whether shear wave elastography (SWE) parameters, combined with dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and physical performance assessments, can help diagnose sarcopenia in older adults. The main questions it aims to answer are:
- Are SWE-derived muscle stiffness parameters associated with muscle mass, muscle strength, and physical performance?
- Can an integrated model including SWE parameters accurately identify sarcopenia compared with the DXA-based diagnosis?
Read more
Researchers will compare participants with sarcopenia to those without sarcopenia, to see if SWE parameters differ between groups and contribute to sarcopenia prediction.
Participants will:
- Undergo shear wave elastography of selected skeletal muscles
- Receive a DXA scan to measure appendicular skeletal muscle mass
- Receive a BIA measurement of body composition
- Complete muscle strength and physical performance assessments
- Conditions
- Sacropenia
- Keywords
- Sacropenia, DXA, Body composition, shear wave elastography, BIA measurement, Geriatrics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Sarcopenia | Participants diagnosed with sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2025 consensus, defined as concurrent low muscle strength and low DXA-measured appendicular skeletal muscle mass. | |
| Non-sacropenia | Participants who do not meet the AWGS 2025 criteria for sarcopenia. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic accuracy of shear wave elastography parameters for sarcopenia
Area under the receiver operating characteristic curve (AUC), sensitivity, and specificity of SWE parameters, alone and combined with BIA and physical performance measures, for identifying sarcopenia as defined by the AWGS 2025 consensus.
Measured: Within 2 weeks of enrollment
Secondary outcomes (3)
Appendicular skeletal muscle mass index measured by DXA
Appendicular skeletal muscle mass divided by height squared (kg/m²), measured by dual-energy X-ray absorptiometry.
Measured: Within 2 weeks of enrollment
Skeletal muscle mass index measured by BIA
Appendicular skeletal muscle mass divided by height squared (kg/m²), measured by bioelectrical impedance analysis.
Measured: Within 2 weeks of enrollment
Handgrip strength
Maximum handgrip strength (kg) of the dominant hand measured with a handheld dynamometer.
Measured: Within 2 weeks of enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Nov 2026
- Study start21 Oct 2026
- Primary completionDec 2026 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SacropeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kaohsiung Veterans General Hospital.
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ming Hsuan Huang, Kaohsiung Veterans General Hospital.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07915310
- Sponsor's protocol ID
- 26-CT7-09(260617-1)
- Other IDs
- KSVGH115-181
- Status last verified
- Nov 2026
- First submitted
- 28 Oct 2026
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared publicly due to participant privacy and confidentiality requirements under Taiwan's Personal Data Protection Act and the conditions of institutional review board approval. De-identified data may be made available from the corresponding author upon reasonable request, subject to approval by the institutional review board.
Publications
Chen LK, Hsiao FY, Akishita M, Assantachai P, Lee WJ, Lim WS, Muangpaisan W, Kim M, Merchant RA, Peng LN, Tan MP, Won CW, Yamada M, Woo J, Arai H. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update. Nat Aging. 2025 Nov;5(11):2164-2175. doi: 10.1038/s43587-025-01004-y. Epub 2025 Nov 4.
PubMed 41188603
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multimodal Assessment of Sarcopenia Using Shear Wave Elastography, Dual-Energy X-ray Absorptiometry, Bioelectrical Impedance Analysis, and Physical Performance Measures
- ClinicalTrials.gov ID
- NCT07915310
- Acronym / sponsor ID
- 26-CT7-09(260617-1)
- Conditions
- Sacropenia
- Keywords
- Sacropenia, DXA, Body composition, shear wave elastography, BIA measurement, Geriatrics
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Kaohsiung Veterans General Hospital.University, hospital or other
- Study start
- 21 Oct 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 4 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn whether shear wave elastography (SWE) parameters, combined with dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and physical performance assessments, can help diagnose sarcopenia in older adults. The main questions it aims to answer are:
- Are SWE-derived muscle stiffness parameters associated with muscle mass, muscle strength, and physical performance?
- Can an integrated model including SWE parameters accurately identify sarcopenia compared with the DXA-based diagnosis?
Researchers will compare participants with sarcopenia to those without sarcopenia, to see if SWE parameters differ between groups and contribute to sarcopenia prediction.
Participants will:
- Undergo shear wave elastography of selected skeletal muscles
- Receive a DXA scan to measure appendicular skeletal muscle mass
- Receive a BIA measurement of body composition
- Complete muscle strength and physical performance assessments
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sarcopenia | – | –Participants diagnosed with sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2025 consensus, defined as concurrent low muscle strength and low DXA-measured appendicular skeletal muscle mass. |
| Non-sacropenia | – | –Participants who do not meet the AWGS 2025 criteria for sarcopenia. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
- Study population
- Participants will be recruited from the outpatient clinics or inpatient ward of Kaohsiung Veterans General Hospita, Taiwan.
Key inclusion criteria (4 listed)
- Adults aged 65 years and older
- Able to walk independently, with or without an assistive device
- Able to understand study procedures and provide written informed consent
- Able to perform related exam
Key exclusion criteria (8 listed)
- Implanted electronic medical devices (e.g., cardiac pacemaker or defibrillator), which contraindicate BIA measurement
- Metal implants or prostheses in the regions measured by DXA or ultrasound
- History of fracture or surgery of the lower extremities within the past 6 months
- Neuromuscular disease affecting skeletal muscle (e.g., stroke with residual limb weakness, Parkinson's disease, myopathy, or amyotrophic lateral sclerosis)
- Skin lesions, wounds, or infection at the ultrasound measurement sites
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Diagnostic accuracy of shear wave elastography parameters for sarcopenia
Time frame: Within 2 weeks of enrollment
Area under the receiver operating characteristic curve (AUC), sensitivity, and specificity of SWE parameters, alone and combined with BIA and physical performance measures, for identifying sarcopenia as defined by the AWGS 2025 consensus.
3 secondary outcomes
Appendicular skeletal muscle mass index measured by DXA
Time frame: Within 2 weeks of enrollment
Skeletal muscle mass index measured by BIA
Time frame: Within 2 weeks of enrollment
Handgrip strength
Time frame: Within 2 weeks of enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Background: PubMed 41188603Chen LK, Hsiao FY, Akishita M, Assantachai P, Lee WJ, Lim WS, Muangpaisan W, Kim M, Merchant RA, Peng LN, Tan MP, Won CW, Yamada M, Woo J, Arai H. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update. Nat Aging. 2025 Nov;5(11):2164-2175. doi: 10.1038/s43587-025-01004-y. Epub 2025 Nov 4.
- Individual participant dataSharing planned: No. Individual participant data will not be shared publicly due to participant privacy and confidentiality requirements under Taiwan's Personal Data Protection Act and the conditions of institutional review board approval. De-identified data may be made available from the corresponding author upon reasonable request, subject to approval by the institutional review board.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sacropenia, run by Kaohsiung Veterans General Hospital. at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ming Hsuan Huang, MD (+886 073422121, min0711@vghks.gov.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnostic accuracy of shear wave elastography parameters for sarcopenia (time frame: Within 2 weeks of enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07915310, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.